Routine Use of Photodynamic Diagnosis of Bladder Cancer: Practical and Economic Issues

Zaak, 2005, Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy, BJU Int, 96, 217, 10.1111/j.1464-410X.2005.05604.x

Van der Meijden, 2005, EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ, Eur Urol, 48, 363, 10.1016/j.eururo.2005.05.011

Zaak, 2001, Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies, Urology, 57, 690, 10.1016/S0090-4295(00)01053-0

Kriegmair, 2002, Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy, J Urol, 168, 475, 10.1016/S0022-5347(05)64661-7

Riedl, 2001, Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer, J Urol, 165, 1121, 10.1016/S0022-5347(05)66442-7

Filbeck, 2002, Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?, Urology, 60, 1025, 10.1016/S0090-4295(02)01961-1

Jichlinski, 2003, Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer––a multicenter study, J Urol, 170, 226, 10.1097/01.ju.0000060782.52358.04

Obermann, 2003, Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses, J Pathol, 199, 50, 10.1002/path.1259

Filbeck, 1999, 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors, Urology, 53, 77, 10.1016/S0090-4295(98)00430-0

Grimbergen, 2003, Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy, Eur Urol, 44, 51, 10.1016/S0302-2838(03)00210-0

Botteman, 2003, The health economics of bladder cancer: a comprehensive review of the published literature, Pharmacoeconomics, 21, 1315, 10.2165/00019053-200321180-00003

Sanger, 2005, The economic consequences of prostate and bladder cancer in the UK, BJU Inter, 95, 59, 10.1111/j.1464-410X.2005.05249.x

Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031

Hedelin, 2002, The cost of bladder tumour treatment and follow-up, Scand J Urol Nephrol, 36, 344, 10.1080/003655902320783845

Oosterlinck, 2006

Lotan, 2006, Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis, Cancer, 107, 982, 10.1002/cncr.22084

Zaak, 2002, Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions, Cancer, 95, 1234, 10.1002/cncr.10821

Hungerhuber, 2007, Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder, Urology, 69, 260, 10.1016/j.urology.2006.10.015

Stenzl, 2001, Fluorescence assisted transurethral resection of bladder tumours: Is it cost effective?, Eur Urol, 39, 31

Orellana, 2002, Reform in German hospital funding system concerns doctors, Lancet, 359, 328, 10.1016/S0140-6736(02)07561-X

Denzinger, 2008, Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study, BJU Int, 101, 566, 10.1111/j.1464-410X.2007.07314.x

Fradet, 2007, A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study, J Urol, 178, 68, 10.1016/j.juro.2007.03.028